Tarsus Pharmaceuticals, Inc.
TARS
Rang in aandelen
#4590
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aandeelprijs
$71.12
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$3.33B
Verandering (1 dag)
2.33%
Verandering (1 jaar)
0.42%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Categorie
Healthcare
Winst voor Tarsus Pharmaceuticals, Inc. (TARS)
Winst in Jun 2026 TTM: $-44.05M
Volgens de meest recente financiële verslagen van Tarsus Pharmaceuticals, Inc. bedraagt de huidige winst van het bedrijf $-44.05M. In 2023 behaalde het bedrijf een winst van $-135.89M, een daling ten opzichte van de winst van 2022, die $-62.10M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Tarsus Pharmaceuticals, Inc. van 2018 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
